 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Is IGGI finally starting to move ? It closed at $3.00 up .625 for the day. That's a 26.32% increase in one day! Here's the low down on IGGI from Stockline awhile back: June 4, 1996 stockline.com e-mail: Invest@stockline.com IGG International, Inc. IGGI $4.63 Exceptional Opportunity I research and perform due diligence on almost a thousand companies per year and from these I select 10 to 20 companies that I feel very comfortable about and recommend them to my subscribers. By being selective and eliminating 98% of the companies, I improve your success rate for profitable speculation. Then you select a few of my recommendations that best suit your objectives and, provided you purchase the shares at a reasonable price, you profit handsomely. I only mention this selection process to point out that I am usually disappointed with the fundamental analysis of most companies. It is rare that I find a company that excites me enough to contact management for additional information. So you can imagine my excitement when I run across an exceptional opportunity like today's recommendation, IGG International, Inc. As well as our recommendations have performed during 1996, I fully believe IGG has the potential to dwarf all previous percentage gains that I have so proudly reported. It won't happen in the next two or three weeks and possibly not in the next quarter or two but IGG could become a very high priced stock if management is able to advance and complete the projects it has been developing for the past 10 years. IGG International is a biotechnology company focused on developing complex carbohydrate compounds, derived from naturally occurring substances, for pharmaceutical and agricultural applications. IGG has two operating subsidiaries: International Gene Group, Inc. and Agricultural Glycosystems, Inc. International Gene Group is developing carbohydrate compounds as therapeutics for the treatment of cancer, cancer metastasis and HIV. Agricultural Glycosystems is developing and commercializing carbohydrate compounds that have demonstrated an ability to improve plant resistance to fungal infection. Technology Overview Carbohydrate compounds are being recognized as a rapidly growing area of therapeutic product development. IGG is developing several classes of these compounds based on the discovery of their biological activity by the company's scientific founder and CEO, David Platt, Ph.D. Dr. Platt, an accomplished carbohydrate chemist, isolated a specific fragment of pectin which acts as an anti-adhesive to prevent cancer cells from binding together and metastasizing. Pre-clinical studies on IGG's compound derived from pectin have been published in the Journal of the National Cancer Institute. The journal article outlined the compound's ability to inhibit spontaneous metastasis in a mouse melanoma cancer model. The company has identified the activities, determined the structure and successfully replicated the isolation process of the active fragment of pectin. In addition, IGG has developed a method to produce large quantities of the compound at a low cost. Dr. Platt has filed a patent for the use of pectin or pectin derivatives as a cancer treatment. I understand human trials could start as early as the first quarter of 1997, just a bit more than six months away. In addition to his work on pectin, Dr. Platt is developing a second class of naturally occurring complex carbohydrates as immune modulators. In pre-clinical studies, this group of compounds has demonstrated in mice, the capability to stimulate the immune system to fight against cancer and a virus similar to HIV (MuLV). Research into this class of compounds is ongoing. Agricultural Glycosystems is developing and commercializing non-toxic carbohydrate compounds for improved plant health. The compounds are designed to stimulate a plant's internal immune mechanisms to fight against disease and infection. A lead product has been identified, AGI 02-105F. Field studies on a variety of plants has shown the compound to be highly effective in controlling disease without impacting the plant. The potential market world-wide is in the billions of dollars and if only a small percentage of the market is captured, the earnings for IGG would be tens of millions of dollars. An independent research report by Frost and Sullivan predicts sales of carbohydrate based therapeutics to reach $5.25 billion by the year 2000. IGG is emerging as the innovative leader in this new class of therapeutic compounds. Last January IGG announced that its subsidiary, Agricultural Glycosystems signed an exclusive, worldwide licensing agreement with the Government of Israel, the co-developers, to commercialize the product. This fungicide is now awaiting approval by the Environmental Protection Association and the company expects to obtain approval in the future (6 to 9 months is my guess but it could be sooner) since the product is completely non-toxic. Recommendation The company isn't making any profits right now but the burn rate is fairly low and the share price should rise in anticipation of huge earnings down line. IGG is likely to be a high priced stock six to 18 months from now but the biggest profits will come from the cheapest shares. If the management of IGG International achieves its goals, your grandchildren's will be telling their children about how you amassed a fortune for the family and about the company that made the entire family wealthy. It's not a matter of buying shares in this company, it's a matter of buying enough at the right price. The shares were as high as US$6.00 in the last 12 months and I'm confident the stock will exceed that price in the near term. The shares trade lightly on NASD OTC Bulletin Board but patient buyers should probably be able to buy between $5.00 and $6.00. Don't push the share price through $6.00 for a few weeks. Give current shareholders ample time to get a quote and decide to part with their shares. If we don't get filled at our price by June 20th, we might go a little higher at that time. The shares are traded by market makers so you usually have to buy at their offering price which is currently $4.63 but that will move higher as our orders are entered tomorrow morning. It appears that Public Securities is the most active market maker and your broker's trading desk can reach them at 1-800-964-4551. ____________________________________ IGG International, Inc. One Kendall Square, Building 300 Cambridge MA 02139 * For additional information * Jim Czirr at (208) 263-6695 Symbol: IGGI * Exchange: NASDAQ OTC Bulletin Board * Current price: US$4.63 * Range: $0.625 - $6.125 * Started trading: August 14, 1995 * Shares outstanding: 8.4 million * Of which insiders hold 5.8 million in restricted shares * Float: 2.6 million * CUSIP: A449546100 ********************** Disclaimer: Stock Line is published by Legacy Communications Inc. Neither the information nor any opinions expressed constitutes a solicitation by us of the purchase or sale of any securities. There are no guarantee that any recommendation will be profitable or will equal past results, particularly in the case of low-priced shares known as penny stocks. Officers, directors and employees of the publisher may or may not have positions in the securities mentioned or recommended. Investors should be aware that the purchase of securities issued by foreign companies involves certain risks which may not pertain to securities of United States issuers. Not all broker-dealers are able to handle purchase and sale transactions involving foreign securities. Information concerning foreign securities that is generally available to the public will often be less comprehensive and less reliable. The value of foreign securities is affected by fluctuation in foreign currency exchange rates. The articles and information published is believed to be from reliable sources but cannot be guaranteed. The information contained in these reports may not be complete. Investors should always consult with their securities advisor before making any investment decision. | ||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2026 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |